Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Garetosmab
Regeneron UK Limited
Fibrodysplasia Ossificans Progressiva
1 trial -
Gefarnate
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
Gefitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.
Gilead Sciences Pty Limited
PD-L1 Positive Metastatic Triple-Negative Breast Cancer
1 trial -
Gemcitabine Eugia 40 mg/ml solution à diluer pour perfusion, RILVEGOSTOMIG, Cisplatine Teva 1 mg/ml solution à diluer pour perfusion.
CERO THERAPEUTICS HOLDINGS, INC.
Hihg risk of cholangiocarcinoma intra hépatic resectable
1 trial -
Gemcitabine,Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Generic Estradiol Vaginal Cream USP, 0.01%
Teva Pharma GmbH
Atrophic Vaginitis
1 trial -
Genotype-guided dosingTaiwan algorithm for warfarin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stroke
1 trial -
Gilteritinib
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
Gonal-F
The First People's Hospital of Lianyungang
Anovulation
1 trial -
Grafalon 20 mg/ml concentrato per soluzione per infusione
The George Institute
To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.
1 trial -
Granules for oral suspension, N-Acetyl-L-Leucine
Intrabio Ireland Limited
Niemann-Pick disease type C
1 trial -
Granulocyte Colony-Stimulating Factor(G-CSF)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Myelodysplastic Syndrome
2 trials -
H006629, H006629, H006629, LEVODOPA AND DECARBOXYLASE INHIBITOR , H006629
Zambon SpA
Motor fluctuations in advanced Parkinson’s disease
1 trial -
H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)
GlaxoSmithKline
Influenza
1 trial -
HIPEC with neoadjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
HVA
The First People's Hospital of Lianyungang
Newly Diagnosed Acute Myeloid Leukemia With High Risk
1 trial -
Herceptin 150 mg powder for concentrate for solution for infusion, DS-8201a, Perjeta 420 mg concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion
Ningbo Cancer Hospital
Early stage HER2-positive breast cancer
1 trial -
Herzuma 150 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DS-8201a, CAPECITABINE, 5-Fluorouracil Ebewe 50 mg/ml concentrat pentru soluţie injectabilă/perfuzabilă, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CAPECITABINE, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Daiichi Sankyo
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer
1 trial -
Herzuma 420 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, Perjeta 420 mg concentrate for solution for infusion, CYCLOPHOSPHAMIDE, DS-8201a, PACLITAXEL, DOXORUBICIN, Herzuma 150 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
AstraZeneca AB
Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)
1 trial -
Home non-invasive ventilation
United Therapeutics Europe Ltd
Hypercapnic Respiratory Failure
1 trial -
Houyanqing Oral Liquid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Cancinoma (NPC)
1 trial -
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Norovirus Infections
1 trial -
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources